We report on the long-term safety of AAV2.sFlt-1 (a recombinant adeno-associated virus serotype 2 carrying the soluble form of the Flt-1 receptor) injection into the subretinal space of non-human primates. Levels of sFlt-1 protein were significantly higher (Po0.05) in the vitreous of four out of five AAV2.sFlt-1-injected eyes. There was no evidence of damage to the eyes of animals that received subretinal injections of AAV2.sFlt-1; ocular examination showed no anterior chamber flare, normal fundus and electroretinography responses equivalent to those observed before treatment. Notably, immunological analysis demonstrated that gene therapy involving subretinal injection of AAV2.sFlt-1 does not elicit cell-mediated immunity. Biodistribution analysis showed that AAV2.sFlt-1 could be detected only in the eye and not in the other organs tested. These data indicate that gene therapy with subretinal AAV2.sFlt-1 is safe and well tolerated, and therefore promising for the long-term treatment of neovascular diseases of the eye.
INTRODUCTION

Neovascularization in the adult eye is a serious complication of long-term diabetes and age-related macular degeneration (AMD).
It has been associated with the upregulation of vascular endothelial growth factor (VEGF). 1 --3 The role of VEGF in ocular neovascularization has been demonstrated in animal models directly 4 --7 and indirectly. 8 --11 Anti-VEGF therapies, utilizing antibodies (for example, ranibizumab (Lucentis, Genentech, South San Francisco, CA, USA), bevacizumab (Avastin, Genentech)) and aptamers (for example, pegaptanib sodium (Macugen, Eyetech Pharmaceuticals, Lexington, MA, USA)) to neutralize VEGF, have been successfully used to treat AMD. 12 --14 Over time, the safety of ocular anti-VEGF treatments has been established, and intravitreal injection of ranibizumab is now the standard treatment for wet AMD. Thus, there is an increasing amount of data suggesting that long-term anti-VEGF therapy helps retain and improve the vision of AMD patients. 13, 15 However, repeat intravitreal injections of recombinant protein every 4 --6 weeks, as required to achieve clinically relevant improvements in patients with AMD, 16, 17 is very inconvenient and poses an increased risk of complications such as endophthalmitis 18 and retinal pigment epithelium tears. 19 To overcome these shortcomings, we investigated recombinant adeno-associated virus serotype 2 (AAV2)-mediated delivery of a naturally occurring antiangiogenic agent into the eye. 20 VEGF exerts its action via specific fms-like receptors, Flt-1 and Flk-1/KDR, which are high-affinity receptor tyrosine kinases. 21 A soluble form of the Flt-1 receptor (sFlt-1), which is naturally present in the body, exerts its antiangiogenic activity by inhibiting VEGF through two mechanisms: sequestration of VEGF and formation of inactive heterodimers with the membrane-spanning isoforms of the VEGF receptors Flt-1 and Flk-1/KDR. 22 As a potent, naturally occurring inhibitor of angiogenesis, sFlt-1 is an attractive tool for the treatment of neovascular diseases. Several studies have used recombinant virus to upregulate sFlt-1 expression in animal models of choroidal neovascularization 23 --25 and retinal neovascularization. 9, 26, 27 Although these studies used a variety of delivery methods and ocular neovascularization models, they all showed that upregulation of sFlt-1 expression in the eye was efficacious and highly beneficial in inhibiting ocular neovascularization. Our previous studies have also demonstrated the efficacy of sFlt-1 overexpression mediated by recombinant adenovirus (Ad.sFlt-1) and AAV2 carrying the human sFlt-1 gene (AAV2.sFlt-1) in slowing the progression of or inhibiting neovascularization in a rat model of corneal neovascularization, 5, 28 in rat and non-human primate models of laser photocoagulation-induced choroidal neovascularization 11 and in a transgenic mouse model of retinal neovascularization. 11, 20 AAV2 appears to be one of the most promising recombinant viral vectors for clinical gene therapy applications. AAV2 is derived from a nonpathogenic adeno-associated virus, which helps to allay concerns associated with the use of recombinant viruses. Recent advances in the preparation of clinical grade AAV2 vectors resulted in several clinical trials targeting diseases such as cystic fibrosis, 29, 30 inflammatory arthritis, 31 Parkinson's disease, 32 Canavan's disease, 33 hemophilia, 34, 35 Batten's disease 36 and, more recently, Leber's congenital amaurosis. 37 --39 The majority of these clinical trials have reported promising results with no serious adverse events observed. However, one patient in an inflammatory arthritis trial died unexpectedly and cell-mediated immunity was not excluded as a contributing factor. 40 In another trial involving hemophilia patients, vigorous cytotoxic T-lymphocyte reactions leading to transient transaminitis were reported. 41 With these two serious adverse events possibly associated with AAV2, the safety of each of the constructs per se and the immune response to AAV2 must be evaluated in more detail.
The advantage in using AAV2-mediated upregulation of sFlt-1 to slow the progression of ocular neovascularization is that longterm expression of sFlt-1 is achieved by a single intraocular injection of AAV2.sFlt-1 without eliciting deleterious effects in rodents 20 or non-human primates. 20 These data support the high potential of developing sFlt-1-based therapies for human use. For gene therapy protocols to be accepted in clinical practice, the perceived risks associated with off-target biodistribution or gene expression, potential toxicity and immune responses that may be elicited by the therapy must be addressed. In this study we investigated the safety of AAV2.sFlt-1 therapy, determined the biodistribution of AAV2.sFlt-1 and examined whether AAV2.sFlt-1 injected into the subretinal space affects retinal function as well as systemic and ocular sFlt-1 levels and whether it induces a cellular immune response.
RESULTS
Assessment of AAV2.sFlt-1
Electron microscopy of negatively stained preparations of this lot of AAV2.sFlt-1 showed presence of virus particles with diameters ranging from 21 to 24 nm (Figure 1a ). There were very few (o1%) empty capsids (Figure 1a , arrow) present. Silver staining of the electrophoresed AAV2.sFlt-1 revealed three distinct bands of sizes 62, 72 and 85 kDa (Figure 1b ) and the identity of these three bands was confirmed by western blotting to correspond to Vp1, Vp2 and Vp3, respectively, using the anti-AAV capsid protein clone B1 monoclonal antibody (Figure 1c ).
Clinical and functional assessment of non-human primate eyes Subretinal delivery of AAV2.sFlt-1 did not affect retinal morphology and function. Following the experimental plan presented in Figure 2 , non-human primate eyes were examined clinically by color fundus photography and fluorescein angiography both before and after injection with AAV2.sFlt-1 and recombinant sFlt-1 protein. A list of all the procedures performed and data collected from the experimental animals during the full course of the study is summarized in Supplementary Table 1. All non-human primate eyes were normal at the time of injection. Funduscopic examination showed blood vessels originating from a well-defined circular optic disc and converging around the macula (Figures 3a and e) . Fluorescein angiography showed a network of robust blood vessels (Figures 3c and g ).
Following injection, there was no evidence of ocular pathology, other than the effects expected from the retinal surgery, such as mild conjunctiva reaction. Tobramycin was applied and all injected eyes recovered from the surgery within 3 days without any apparent damage. The bleb introduced by subretinal injection had almost completely resolved within 24 --48 h post injection. The cornea and the lens remained clear and there was no anterior chamber flare or cellular infiltration detected in the vitreous. This was true for eyes receiving direct injection of the recombinant sFlt-1 protein, as well as eyes injected with AAV2.sFlt-1 and AAV2.GFP (AAV2 encoding green fluorescent protein). (Figure 3d, arrow) . Throughout the course of the study, the fundus and retinal vasculature of AAV2.GFP-and AAV2.sFlt-1-injected non-human primates were normal. All nonhuman primates ate and behaved normally soon after the surgery and remained healthy throughout the course of the study.
Typical electroretinography (ERG) responses before and after injection of AAV2.sFlt-1 and recombinant sFlt-1 protein are shown in Figure 4 and the group data are shown in Table 1 . Before injection, there was no statistically significant difference (P40.05, Student's t-test) in combined rod-cone bright flash ERG (maximal ERG) responses between the AAV2.sFlt-1-injected and control eyes There was also no statistically significant difference in maximal ERG parameters (a-wave and b-wave amplitudes, a-wave and bwave implicit times) between injected and control eyes at any of the time points examined. In addition, there was no significant difference (P40.05, one-way analysis of variance) in maximal ERG parameters between all the time points (3, 6, 9 and 12 months) examined in the control, as well as the injected eyes (Table 1) . Statistical analysis was not performed on AAV2.GFP (n ¼ 2) and sFlt-1 (n ¼ 1) protein-injected eyes because of the small sample numbers. Only responses from the flash intensity of 1.0 log cd s m À2 (maximal ERG) were presented here.
Effect of injection on plasma and ocular sFlt-1 levels Vitreous sFlt-1 levels were higher in AAV2.sFlt-1-injected eyes. The protein levels of sFlt-1 in the plasma and aqueous humor are summarized in Table 2 . Before injection, the plasma sFlt-1 protein levels in the eight experimental non-human primates ranged from 86.5 ± 1.1 to 193.0 ± 2.7 pg ml --1 . Following injection, the plasma sFlt-1 protein levels ranged from 82.5±4.4 to 168.8±7.2 pg ml --1 at 14 days, 60.8 ± 1.4 to 226.3 ± 1.9 pg ml --1 at 2 months, 47.1 ± 0.8 to 149.8 ± 2.1 pg ml --1 at 6 months and 47.2 ± 3.6 to 139.3 ± 2.9 pg ml --1 at 12 months. Significant fluctuations in plasma sFlt-1 protein levels were observed within and between animals and they did not appear to be associated with AAV2.sFlt-1 injection. In contrast, higher levels of sFlt-1 protein were clearly present in the majority of the vitreous of AAV2.sFlt-1-injected eyes compared with their respective contralateral uninjected eyes ( Figure 5 ). The differences in sFlt-1 protein levels between the injected and uninjected contralateral eyes were statistically significant (Po0.05, Student's t-test) in four of the five AAV2.sFlt-1-injected non-human primates. There was no statistically significant difference (P ¼ 0.13) in sFlt-1 protein levels between the vitreous of recombinant sFlt-1 protein-injected eye (214.9±16.0 pg ml --1 ) and the control uninjected contralateral eye (161.4±31.7 pg ml --1 ) at 3 months post injection (data not shown). Similarly, there was no statistically significant difference (P ¼ 0.16, Student's t-test) in vitreous sFlt-1 protein level in the control non-human primate (125.6±32.1 vs 172.9±31.7 pg ml --1 ; Figure 5 ). sFlt-1 protein levels were higher in the aqueous humor of AAV2.sFlt-1-injected eyes (Table 2 ), but there were not enough aqueous humor samples (n ¼ o3) from AAV2.GFP and recombinant sFlt-1 protein-injected animals to test whether the differences were statistically significant.
Biodistribution of AAV2.sFlt-1 AAV2.sFlt-1 was not detected in nonocular tissues. A real-time PCR assay was used to examine the biodistribution of AAV2.sFlt-1 in nonocular tissues. In each PCR run, a standard curve was generated using different gene copy numbers of linearized plasmid DNA (pAAV.sFlt-1) containing the sFlt-1 sequence. pAAV2.sFlt-1 was the recombinant AAV2.sFlt-1 plasmid used to generate the AAV2.sFlt-1 gene therapy vector. The gene copy numbers of AAV2.sFlt-1 present in the different samples---left eye; right eye; optic nerve; cervical lymph nodes; axillary lymph nodes and submandibular lymph nodes---are presented in Supplementary Table 2 . AAV2.sFlt-1 genome was not detected in genomic DNA samples isolated from tissues obtained from the uninjected control and the AAV2.GFP-injected non-human primates. Similarly, in the AAV2-sFlt-1-injected non-human primates, the AAV2.sFlt-1 genome was not detected in any of the tissues examined, including the lymph nodes, liver, spleen, heart, lung, brain and corneal samples. The AAV2.sFlt-1 genome was detected in the optic nerve of one out of five eyes injected with AAV2.sFlt-1. This positive animal (8514) expressed AAV2.sFlt-1 genome at a low level of 2249.98 ± 90.63 genome copy number per mg of genomic DNA.
We performed enzyme-linked immunosorbent assay to test for the presence of AAV2 capsids in a number of tissues. AAV2 capsids were not detected in any of the serum samples collected before injection or in samples collected at 5 days, 14 days or 1 month after injection from animals injected with AAV2.sFlt-1 or AAV2.GFP (data not shown). AAV2 capsids were also not detected in the aqueous humor, vitreous, spleen, axillary lymph nodes and cervical lymph nodes of the control uninjected, recombinant sFlt-1 protein-injected and AAV2.sFlt-1-injected (M999, M8524) non-human primates (data not shown). M999 and M8524 were euthanized at 3 and 9 months post injection, respectively. This assay was not performed on tissues collected from the AAV2.sFlt-1-injected non-human primates that were euthanized at 12 months post injection.
Immunogenicity studies AAV2.sFlt-1 gene therapy did not elicit a cellular immune response. Cellular immune responses generated by AAV vectors are incompletely understood, mainly because of the paucity of reagents required to analyze such responses. Enumerating major immune cell subsets is a commonly used method for measuring the potential immune response. Utilizing a panel of antibodies (see Supplementary Table 3) , we monitored the numbers of major immune subsets in the blood before injection and at 14 days, 3 months and 9 months following subretinal delivery of recombinant sFlt-1 protein, AAV2.sFlt-1 or AAV2.GFP. Although some non-human primates showed variation in their immune compartments during the course of the treatment, there were no consistent trends in the frequencies of all the immune cell subsets analyzed across animals in the various treatment groups and any changes detected were not significant (see Supplementary Figure 1 ).
Although these large-scale analyses suggest that subretinal injection of AAV2.sFlt-1 does not have a significant impact on systemic host immune responses, the activation and proliferation status of T and B cells were assessed further using novel techniques to monitor any potential immune activation in more detail. A recent study showed that immune activation in T-cell subsets can be evaluated by monitoring the expression of the activation markers CD38, HLA-DR and Ki67 and the downregulation of intracellular Bcl-2 (B-cell lymphoma 2). 42 Using a similar approach, we monitored immune activation in CD4 þ T cells, CD8 þ T cells and CD21 þ B cells using Ki67, HLA-DR and Bcl-2. Activated T cells display an effector phenotype characterized by the expression of the differentiation marker HLA-DR and the cell cycle-associated nuclear antigen Ki-67, the latter used as a marker for proliferation. 43 Resting T cells do not express Ki-67, whereas cycling or recently divided T cells upregulate Ki-67 expression. 44, 45 Some degree of Ki-67 expression is detected as part of homeostatic cell cycling. The data in Figure 6a show examples of Ki-67 expression in CD8 þ T cells from animals receiving recombinant sFlt-1, AAV2.sFlt-1 or AAV2.GFP. Variation in the basal levels of Ki-67 expression was observed among animals before treatment. Although Ki67 expression also varied over the course of treatment, intraocular administration of any of the vectors did not directly impact Ki67 expression. Figure 6b shows the variation in Ki67 expression in all animals in the study over the period of analysis. Expression of Ki67 on CD4 þ T cells (Figures 6c and d ) and CD21 þ B cells (Figure 6e ) also varied over the study period, but no significant increase in Ki67 was observed following administration of the AAV2.sFlt-1. Importantly, HLA-DR þ Ki-67 þ cells were detected at very low levels in all the non-human primates tested (data not shown). In conclusion, the available data indicate that although proliferating CD4 þ T cells, CD8 þ T cells and B cells can be detected, this occurs independently of AAV2-sFlt-1 therapy. In addition, the immune cells that proliferate do not display an activated effector phenotype. Overall, these data suggest that AAV2-sFlt-1 therapy does not result in systemic immune activation.
DISCUSSION
Gene therapy is one of the most promising strategies for treating chronic diseases. When evaluating gene therapy for routine clinical intervention, the method of administration, the effect of the delivery vector and the effect of the therapeutic gene must be assessed for efficacy and safety. In the context of our study, these involved examining (1) the safety of subretinal injection (2) the presence of AAV2 capsid and (3) the effect of overexpression of sFlt-1 on the eye.
Recent human gene therapy clinical trials using an AAV2 vector for the treatment of Leber's congenital amaurosis have provided valuable information about the safety of delivering AAV2 by subretinal injection. 37 --39 Delivery into the subretinal space, although not routinely performed under current practice, is a straightforward clinical procedure for trained vitreoretinal surgeons. The subretinal bleb that is formed resolves within 14 --24 h. 37, 39 In our experience, subretinal injection of AAV2.sFlt-1 was not associated with any adverse effects apart from minor local irritation at the site of injection. Indeed, all examined animals showed flawless reattachment of the retina. 11, 20 Thus, on the basis of our own analyses, as well as recently published reports, 37 --39 we conclude that in the hands of an experienced surgeon, subretinal injection is a safe, although sometimes difficult to reproduce, clinical procedure. 46 Previous large animal studies and data generated by the three human trials provided valuable information on the biodistribution of AAV2 following subretinal injection. Animals have shown only very limited scatter of the vector outside the eye following intraocular administration, 47, 48 and human studies thus far have not reported any dissemination of the vector outside of the eye following subretinal injection. 37, 39 Thus, the evolving consensus is that escape of vector particles is limited following proper placement of the vector in the subretinal space. The presence of recombinant viral genome in the optic nerve has been reported in an earlier study in dogs, 48 and in chiasm of mice and dogs following subretinal injection of AAV2.GFP. 49 However, the presence of the recombinant viral genome, or transgene products, in the optic nerve and chiasm did not have any adverse effect on the health, immune system or vision of the animals. In the current study, it was reassuring to note that AAV2.sFlt-1 genome was only detected in low copy number in the optic nerve of a single animal (M8514) and this did not result in any behavioral abnormality throughout the course of the study nor did it compromise the immune response (Supplementary Figure 1, and Figure 6 ). In addition, any sFlt-1 protein present in the optic nerve would be secreted. Thus, the potential production of low amounts of sFlt-1 protein in the optic nerve is unlikely to represent any risk. Thus, our study on non-human primates demonstrated that, in contrast to intravitreally injected AAV2 constructs, 50 AAV2 constructs injected into the subretinal space remained localized in the eye. Density plots of B-cell populations (CD21 þ ) Ki67 expression are shown for two animals in the study, one AAV2.sFlt-1 treated and the other AAV2.GFP treated. Ki67 staining was performed on frozen lymphocyte samples after the final time point of the study; 1 Â 10 6 events were collected on a FACS Calibur, and analysis was performed using FlowJo.
Nevertheless, biodistribution could be further limited if necessary by restricting transgene expression by using alternative AAV serotypes and/or tissue-specific promoters. sFlt-1 is expressed endogenously, and therefore should not be recognized as a foreign antigen when expressed in an AAVmediated context. Thus, sFlt-1 produced by the gene therapy vector is unlikely to elicit an immune response, a concept supported by previous safety assessment studies. 20 The levels of endogenous sFlt-1 in the serum varied. 51 Human serum and plasma sFlt-1 protein levels from healthy male and female donors range from undetectable levels up to 440 pg ml --1 , with no significant differences observed between male and female donors. 52 In females, sFlt-1 protein levels fluctuate with the menstrual cycle and with pregnancy between B50 and 500 pg ml --1 plasma. In spite of the regular increase in sFlt-1 protein levels, the female vasculature appears to be unaffected, suggesting that systemic sFlt-1 protein levels up to B500 pg ml --1 are safe in females. Furthermore, sFlt-1 levels significantly increase in both men and women with essential hypertension (33 vs 24 ng ml --1 ), in women with prior pre-eclampsia 53 and after thrombolytic therapy for acute myocardial infarction (5.6 vs 26.5 ng ml --1 in males and females, respectively). 54 In this study, sFlt-1 protein levels were within the ranges observed in healthy humans, reaching 380 pg ml --1 in the eye and 80 --180 pg ml --1 in plasma. Peak levels were well within the normal, nontoxic human plasma concentration range, and the majority of sFlt-1 protein remained localized in the retina. Thus, it is unlikely that subretinal AAV2.sFlt-1 could have any physiologically meaningful impact on systemic sFlt-1 levels.
sFlt-1 expression was significantly upregulated in four of the five AAV2.sFlt-1-injected eyes. It is difficult to explain why there was no significant sFlt-1 upregulation in one AAV2.sFlt-1-injected eye (M8530) sampled at 12 months post injection and why there was wide variability in the amount of sFlt-1 protein expressed. The most plausible explanation for these discrepancies is either failed/imperfect subretinal injections 46 or the presence of preexisting neutralizing antibodies. Unfortunately, the presence of pre-existing neutralizing antibodies to AAV2 was not measured in this study. However, in another study involving intravitreal injection of AAV2 constructs, neutralizing antibodies were proposed to be associated with the inconsistent gene expression. 55 No retinal changes were detected in any of the eyes with excess sFlt-1 protein. The benign nature of the excess sFlt-1 protein expressed was best demonstrated by preservation of retinal function using ERG, which is the most direct and objective test available for evaluating retinal function. Based on ERG responses, subretinal injection of AAV2.sFlt-1 did not significantly alter retinal function throughout the course of the study (Table 1) , further attesting to the safety of the therapy.
Systemic cellular immune responses following gene therapy could potentially compromise the efficacy of gene therapy as well as the safety of patients. Although more attention has been paid to pre-existing or therapy-induced humoral immunity, cellmediated immune responses generated by gene therapy could represent a major challenge to the successful application of the technology, as they have the potential to cause systemic, as well as ocular pathology. In previous studies, detailed investigation has been limited, mainly because of the lack of appropriate assays and reagents to assess such cell-mediated immune responses. The detailed assessment described here revealed no AAV-mediated activation of systemic immune responses. Although considerable variation in the presence of lymphocytes was observed over the course of the study, this variation did not coincide with the administration of the gene therapy vectors. Activation of immune cell subsets, including CD8 þ T cells, CD4 þ T cells and B cells, was also assessed using a recently reported assay that analyzes the expression of Ki67, HLA-DR and Bcl-2 to define the activation status of immune cell subsets in situation where antigen-specific reagents are not available. 42 Our results were consistent with other studies describing homeostatic levels of Ki-67 expression in lymphocytes in primates. 45 Importantly, a lack of HLA-DR upregulation provided evidence that systemic immune activation was not induced by gene therapy. There was also no evidence of damage to the eyes of treated animals, with ocular examinations showing no cellular infiltration or other detrimental effects, either immediately after injection or in subsequent examinations. These data support the hypothesis that subretinal administration of our gene therapy vectors did not provoke cellmediated immunity.
A recent study in non-human primates using a similar vector, AAV2.sFlt01, injected intravitreally, showed the vector to be safe overall, but a higher level of inflammation and immune response 50 than we report here was found. Whereas AAV2.sFlt-1 described here encodes the naturally occurring form of the soluble receptor driven by the CMV promoter, AAV2.sFLT01 encodes only one Flt-1 domain 2 linked by 9Gly to a human IgG1 heavy-chain Fc domain to generate a forced homodimer and is expressed by the chicken b-actin promoter. 50, 55, 56 sFlt-1 domain 2 is responsible for the VEGF-A-binding activity of sFlt-1. 57 In this study designed to evaluate preclinical safety, mild-to-moderate inflammation directed against the AAV2 capsid lasting several months was observed in 14 of 18 animals. 50 In addition, this study also showed that following intravitreal injection, biodistribution analysis in rats and monkeys showed that vector was found in the retina, as well as trace amounts in the serum, optic nerve and hindbrain; vector was also found in the contralateral eye of one animal. 50 As both studies used AAV2, the differences from the present study are consistent with previous reports that intravitreal administration results in a greater immune response compared with subretinal administration 58 --60 as well as greater biodistribution outside the eye, including to the brain. 48 In summary, subretinal injection of non-human primate eyes with AAV2.sFlt-1 did not lead to any serious adverse events, vision impairment or dissemination of vector outside the eye. In addition, it did not elicit harmful immunological responses. The results obtained in this preclinical study indicate that gene therapy with subretinal AAV2.sFlt-1 is safe and well tolerated and promising for the long-term treatment of neovascular diseases of the eye.
MATERIALS AND METHODS
AAV vector preparation
The AAV2 sFlt-1 and AAV2.GFP vectors, constructed as previously described, 5 were prepared and purified at the Vector Core Facility (Chapel Hill, NC, USA) by heparin affinity chromatography. The titers were 8 Â 10 12 particles per ml of AAV2.sFlt-1 and 1.9 Â 10 11 transducing units per ml of AAV2.GFP.
Transmission electron microscopy A total of 10 ml (1 Â 10 11 particles) of purified and dialyzed AAV2.sFlt-1 was pipetted onto a glow-discharged copper grid. The grid was washed twice with water and then stained with 2% uranyl acetate. Electron microscopy images were taken with a LEO EM-910 transmission electron microscope (LEO Electron Microscopy Inc., Thornwood, NY, USA) at various magnifications at the University of North Carolina microscopy laboratories.
Silver staining
NuPage 5 Â Loading Dye (Invitrogen, Carlsbad, CA, USA) and b-mercaptoethanol were added to 20 ml of purified and dialyzed AAV2.sFlt-1 (1 Â 10 10 particles). The mixture was boiled for 10 min and loaded onto a NuPage 10% Bis-Tris gel (Invitrogen). Electrophoresis was performed with the XCell SureLock minicell (Invitrogen) for 2 h at 100 V in 1 Â NuPage MOPS (morpholinepropanesulfonic acid) buffer. Following electrophoresis, the gel was stained using a SilverXpress Silver Stain kit (Invitrogen) following the manufacturer's instructions.
Western blot
NuPage 5 Â Loading Dye (Invitrogen) and 2-mercaptoethanol were added to 20 ml of purified and dialyzed AAV2.sFlt-1 (1 Â 10 10 particles). The mixture was boiled for 10 min and loaded onto a NuPage 10% Bis-Tris gel (Invitrogen). Electrophoresis was performed with the XCell SureLock minicell (Invitrogen) for 2 h at 100 V in 1 Â NuPage MOPS buffer. Proteins were transferred onto a Hybond ECL membrane (GE Healthcare, Bucks, UK) utilizing the XCell II blot module (Invitrogen) according to the manufacturer's protocol. The membrane was blocked in 2% nonfat dry milk dissolved in 1 Â Tris-buffered saline containing 0.1% Tween-20 (TBST). For the detection of AAV capsid proteins, the primary anti-AAV capsid antibody B1 (American Research Products Inc., Waltham, MA, USA) was diluted 1:20 with 2% nonfat dry milk in TBST and incubated overnight at 4 1C. After washing with TBST, the membrane was incubated for 1 h at room temperature with anti-mouse horseradish peroxidase secondary antibody diluted 1:30 000 in 2% nonfat dry milk with TBST. Following multiple washes with TBST, SuperSignal West Pico Chemiluminescent Substrate (Thermo Fisher Scientific Inc., Rockford, IL, USA) was added to the membrane according to the manufacturer's protocol for development. The membrane was then exposed to Amersham Hyperfilm ECL (GE Healthcare).
Animal preparation and anesthesia
Experimentation on non-human primates (Macaca fascicularis) was performed in accordance with the statement for the use of animals in ophthalmic and vision research approved by the Association for Research in Vision and Ophthalmology. The guidelines of the Animal Ethics Committee of the Singhealth Singapore Association for Assessment and Accreditation of Laboratory Animal Care International-accredited were also satisfied. Non-human primates were anesthetized by intramuscular injection of a mixture containing ketamine (20 mg kg --1 body weight) and acepromazine maleate (0.25 mg kg --1 body weight) and subcutaneous injection of atropine sulfate (0.125 mg kg --1 body weight). Their airway, respiration and pulse were monitored during all procedures. Pupils of nonhuman primates were dilated with 2.5% phenylephrine hydrochloride and 1% tropicamide drops (Alcon Laboratories, Frenchs Forest, NSW, Australia).
Microdelivery system and subretinal injection in non-human primates. The injection procedure was performed under aseptic conditions in a surgical theater equipped for non-human primates. The left eyes of eight non-human primates were subretinally injected with AAV2.sFlt-1 (n ¼ 5), recombinant sFlt-1 protein (n ¼ 1, Cell Sciences, Boston, MA, USA) or AAV2.GFP (n ¼ 2), as previously described, 11, 61 but with modifications to the microdelivery system. A 41-gauge subretinal cannula (Bausch and Lomb, Rochester, NY, USA), shortened and fashioned into a bevel tip to allow easier access into the subretinal space, was connected to a flexible pediatric tubing that was in turn connected to a 5-ml syringe. The 5-ml syringe was needed to build up enough suction pressure to draw the entire 100 ml phosphate-buffered saline containing 8 Â 10 11 particles of AAV2.sFlt-1 or 1.9 Â 10 10 transducing units of AAV2.GFP, or 100 ml phosphate-buffered saline containing 10 mg recombinant sFlt-1 protein up the 41-gauge subretinal cannula. The fluid was drawn up under direct viewing using a magnifying lens. Once 100 ml was drawn up, the 5-ml syringe was replaced by a 1-ml tuberculin syringe that was then used to push out the fluid in a controlled manner. The 100 ml virus-or proteincontaining solution was injected into the eye to create a subretinal bleb with a size of about four times the optic disc diameter, as described previously. 11, 61 One uninjected non-human primate was used as control.
Clinical examination
Non-human primates were anesthetized and their pupils were then dilated as described above. The fundi of non-human primates were imaged with a fundus camera (Topcon Corp., Tokyo, Japan) using Kodak Elite 200 ASA slide film.
Electroretinography
Full-field ERGs were recorded (Espion, Diagnosys LLC, Lowell, MA, USA) in both eyes simultaneously using corneal monopolar DTL electrodes. Stimuli were brief white flashes delivered through a Ganzfeld sphere (ColourDome, Diagnosys LLC) with the flash intensity ranging from À3.3 to 1.0 log cd s m À2 . All recordings were performed under scotopic condition after 30 min of dark adaptation. The signals were band-pass filtered between 0.15 and 100 Hz. ERG recording was performed before injection and at 3, 6, 9 and 12 months after injection.
Plasma collection and peripheral blood mononuclear cell (PBMC) preparation
Blood (6 --8 ml) was collected via saphenous venipuncture into heparinized tubes that were inverted several times to mix the blood and heparin. The whole blood was centrifuged at 700 g for 10 min at room temperature. The plasma was removed using sterile transfer pipettes with care taken to avoid disturbance of the white cell pellet. The plasma was placed in 10 ml tubes for a further round of centrifugation at 700 g for 10 min to remove platelets. Following this, the plasma was aliquoted into sterile microfuge tubes and stored at À70 1C until testing. The blood tube was filled with RPMI/10% fetal bovine serum to a final volume of 20 ml and then gently layered onto 10 ml of Ficoll-Paque (GE Healthcare) in a 50 ml centrifuge tube. Following centrifugation at 400 g for 40 min at 20 1C, the buffy coat containing the PBMCs was collected, made up to 50 ml with RPMI/10% fetal bovine serum and then centrifuged at 500 g for 10 min. The supernatant was discarded and red cell lysis buffer was added to the cell pellet to lyze red blood cells remaining. RPMI/10% fetal bovine serum was then added to a final volume of 50 ml and the PBMCs were pelleted by centrifugation at 500 g for 10 min. The resulting PBMC pellet was resuspended in RPMI/10% fetal bovine serum and the cells counted.
Labeling of PBMCs for flow cytometry
Labeling of PBMCs was performed by incubating them with the appropriate fluorochrome-conjugated antibodies for 30 min at 4 1C. The antibodies used (CD3, CD4, CD8, CD11b, CD11c, CD14, CD16, CD21, CD23, CD27, CD28, CD45RA, CD56, CD63L-PE, CD95-FITC, HLA DR, Ki-67 and Bcl-2) were all from BD Bioscience (Franklin Lakes, NJ, USA). Samples were analyzed on a FACS Calibur instrument (BD Bioscience). Appropriately stained controls were used to check compensation for all fluorochromes used. Files of 1 Â 10 6 events were collected using a live CD45 þ gate, although all events were saved for subsequent analysis using the FlowJo software (Tree Star, Ashland, OR, USA).
Quantitation of sFlt-1 protein and AAV2 capsids Human sFlt-1 protein and AAV2 capsids in plasma and vitreous were quantified by enzyme-linked immunsorbent assay using the Quantikine Human sVEGFR1 (R&D Systems, Minneapolis, MN, USA) and AdenoAssociated Virus serotype 2 (American Research Products Inc.) enzymelinked immunosorbent assay kits, respectively, according to the manufacturers' specifications.
Euthanasia and tissue collection
Animals were euthanized by intravenous injection with an overdose of sodium pentobarbital (Lethabarb; Virbac, Milperra, NSW, Australia). The following tissues were collected: optic nerve, eye, cornea, spleen, liver, heart, lungs, brain, axillary lymph nodes and cervical lymph nodes. The vitreous and the aqueous humor were removed from the enucleated eyes before the eyes were fixed in 4% neutral buffered formalin for histology. All tissues were snap-frozen in liquid nitrogen for subsequent genomic DNA extraction. The vitreous and the aqueous humor were stored at À70 1C for subsequent analysis.
Biodistribution studies of injected AAV2.sFlt-1 vector Biodistribution of the AAV2.sFlt-1 vector that was injected into the subretinal space was analyzed by real-time PCR using SYBR Green detection chemistry in triplicate with the iQ5 machine (Bio-Rad, Hercules, CA, USA). Genomic DNA was extracted from the different tissues using the DNeasy Blood & Tissue Kit (Qiagen GmBH, Hilden, Germany) according to the manufacturer's protocol. The integrity of the genomic DNA was examined following agarose gel electrophoresis and the concentration was measured by spectrophotometry. The genomic DNA (0.5 --1.0 mg) was amplified in 20-ml reaction mixes containing Platinum SYBR Green qPCR Supermix-UDG (Invitrogen) and 0.5 mM of each primer. The primer pair used (forward: 5 0 -CACTAGTCCAGTGTGGTGGA-3 0 ; reverse: 5 0 -AGCCAGGAGA CAACCACTTC-3 0 ) was designed with the aid of Primer3 Output (Whitehead Institute, Cambridge, MA, USA) to amplify the region from the vector complementary DNA into the sFlt-1 gene. The amplification profile used was 50 1C for 2 min, 95 1C for 2 min followed by 60 cycles of 95 1C for 20 s, 60 1C for 20 s and 72 1C for 20 s. This was followed by a melting curve analysis, ranging from 60 to 99 1C, with temperature increasing steps of 0.5 1C every 1 min. Baseline and threshold values were automatically determined. A standard curve was set up using linearized plasmid DNA containing the same target sequence. No template controls and a similar set of genomic DNA samples spiked with plasmid DNA containing the target sequence were included in each run.
